IMMUNEONCO-B (01541) announced that executive director Tian Wenzhi has increased his holding of 50,000 H shares.

IMMUNEONCO-B (01541) announced that the Board of Directors has been informed by Dr. Tian Wen-Zhi, the Executive Director, CEO, and Chairman of the Board, that he purchased a total of 50,000 H shares of the company on the public market on November 7, 2025, at an average price of approximately HK$7.9500 per share, representing approximately 0.01% of the total number of issued shares of the company. Following the purchase, Dr. Tian holds a total equity interest in the company of 116 million shares, representing 26.90% of the total issued share capital of the company as of the date of this announcement. Dr. Tian stated that he is confident in the overall development prospects and potential growth of the group. Subject to compliance with applicable laws and regulations, Dr. Tian does not rule out the possibility of further increasing his holdings of the company's shares at an appropriate time.